Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Narrative (Details)

v3.20.4
Revenue Recognition - Narrative (Details)
$ in Millions
12 Months Ended
Dec. 31, 2020
USD ($)
segment
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Revenue from Contract with Customer [Abstract]      
Number of operating segments | segment 2    
Increase in pharma contract liabilities $ 2.0    
Increase in pharma contract liabilities (as a percent) 70.00%    
Increase in capitalized commissions $ 0.2    
Increase in capitalized commissions (as a percent) 24.00%    
Pharma contract liability, revenue recognized $ 2.3 $ 2.2  
Amortization of contract commissions $ 0.8 $ 1.2 $ 1.0